BIO-TECHNE Corp Foreign Pre-Tax Income
BIO-TECHNE Corp (TECH) reported Foreign Pre-Tax Income of $24.06 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign · last filed 2026-08-24
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, foreign for fiscal 2026 was $24.06M, a 106.52% increase from fiscal 2025.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, foreign for fiscal 2025 was $11.65M, a 7.04% increase from fiscal 2024.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, foreign for fiscal 2024 was $10.88M, a 78.32% decline from fiscal 2023.
- BIO-TECHNE Corp income (loss) from continuing operations before income taxes, foreign for fiscal 2023 was $50.20M, a 8.50% increase from fiscal 2022.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Foreign 12 month |
|---|---|
| 2026-06-30 | $24.06M 10-K · filed 2026-08-24 |
| 2025-06-30 | $11.65M 10-K · filed 2026-08-24 |
| 2024-06-30 | $10.88M 10-K · filed 2026-08-24 |
| 2023-06-30 | $50.20M 10-K · filed 2025-08-22 |
| 2022-06-30 | $46.27M 10-K · filed 2024-08-22 |
| 2021-06-30 | $52.51M 10-K · filed 2023-08-23 |
| 2020-06-30 | $31.11M 10-K · filed 2022-08-24 |
| 2019-06-30 | $47.93M 10-K · filed 2021-08-25 |
| 2018-06-30 | $44.40M 10-K · filed 2020-08-26 |
| 2017-06-30 | $30.24M 10-K/A · filed 2019-11-06 |
| 2016-06-30 | $27.33M 10-K · filed 2018-08-27 |
| 2015-06-30 | $32.40M 10-K · filed 2017-09-07 |
| 2014-06-30 | $33.71M 10-K · filed 2016-08-29 |
| 2013-06-30 | $33.17M 10-K · filed 2015-08-31 |
| 2012-06-30 | $32.19M 10-K · filed 2014-08-29 |
| 2011-06-30 | $33.90M 10-K · filed 2013-08-29 |
| 2010-06-30 | $31.59M 10-K · filed 2012-08-29 |
| 2009-06-30 | $33.78M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |